Allisure® allicin  Accepted for Inclusion in  
U.S. Screening Program for Potential SARS Treatments

WASHINGTON, DC – July 14th, 2003 – The National Institute of Allergy and Infectious Diseases (NIAID), in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), has agreed to evaluate Allicin International Limited’s unique standardized allicin extract as a potential treatment or preventative agent for Severe Acute Respiratory Syndrome (SARS).

Allisure® is a patented anti-infective and immune modulator that has shown in numerous studies to protect against gram-positive and gram-negative bacteria and viral, fungal and parasitic infections. Allisure® is one of thousands of compounds that the NIAID is testing to find a treatment for SARS. Under AIL’s cooperative agreement with NIAID and USAMRIID, allicin will also be evaluated against Smallpox, West Nile Virus, Vaccinia and Cowpox.

AIL is a biotechnology company that is pioneering extraction mechanisms for plant based actives that offer a wide range of potential applications in human and animal health. Founded in 1999 and based in Rye East Sussex England the company has more than 20 U.S. and international patents protecting its various allicin extracts. It now supplies exclusively the Dr Herbal Organisation with a number of stand alone healthcare and veterinary products.

Website: www.drherbal.com
For more information, contact:

Peter Josling  
CSO Dr Herbal at pjosling@drherbal.com